Equity: U.S. Pharmaceuticals
With 4 ETFs and over $996.64M in combined AUM, the Equity: U.S. Pharmaceuticals segment provides exposure to the U.S. space with a focus on Health Care securities.
Year-to-date, the best-performing ETF in the segment is the First Trust Nasdaq Pharmaceuticals ETF (FTXH), with a total return of 3.86%. Meanwhile, the most popular ETF is the Invesco Dynamic Pharmaceuticals ETF (PJP) with $385.85MB in assets under management.
Investors should take a look at the (). This fund has been chosen as an Analyst Pick by FactSet, thus is the best ETF for the average investor. has an expense ratio of -- and tracks the .
ETF.com Efficiency Insight
The average efficiency score in the Equity: U.S. Pharmaceuticals segment is 93 out of 100, with the SPDR S&P Pharmaceuticals ETF(XPH) obtaining the highest rating of 96 out of 100.
Costs dominate the discussion around efficiency. ETFs in the segment have an average expense ratio of 0.48% per year, with the SPDR S&P Pharmaceuticals ETF (XPH) having the lowest expense ratio, charging investors 0.35% yearly.
Investors should look for funds with tight tracking, such as the SPDR S&P Pharmaceuticals ETF (XPH), with a 12-month median tracking difference of -0.10%.
ETF.com Tradability Insight
The average tradability score in the Equity: U.S. Pharmaceuticals segment is 81 out of 100, with the SPDR S&P Pharmaceuticals ETF(XPH) obtaining the highest rating of 97 out of 100.
The SPDR S&P Pharmaceuticals ETF (XPH) is the undisputed segment leader when it comes to liquidity. The fund trades 4.06M in daily average volume. Investors should also find ample liquidity in the Invesco Dynamic Pharmaceuticals ETF (PJP), with $2.29M in daily dollar volume.
Use limit orders to trade funds such as the First Trust Nasdaq Pharmaceuticals ETF(FTXH), due to their double-digit market spreads.
ETF.com Fit Insight
The Thomson Reuters US Pharmaceuticals has been selected as the index that most accurately represents the market in question. The benchmark has been selected by the ETF Analytics team at FactSet, according to a series of guidelines to ensure this index accurately captures its market.
Investors trying to match a broad market exposure should pay attention to IHE. This fund obtains a high Fit score and investors should capture market-like returns.
Other funds diverge from the market, by nature of their investment mandates; for example, XPH follows a Equal strategy and obtains a low Fit score compared with our neutral benchmark.